Evidence map›Paper›PMID 33807368›Full record

ReviewMolecules (Basel, Switzerland)2021

Current Knowledge and Perspectives of Pyrrolizidine Alkaloids in Pharmacological Applications: A Mini-Review.

Xianqin Wei, Weibin Ruan, Klaas Vrieling

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Ethnopharmacology and therapeutic potential ofFrontiers in pharmacology · 2023
    Review
  18. Antifungal Agents in Wood Protection-A Review.Molecules (Basel, Switzerland) · 2022
    Review
  19. Article
  20. Alkaloids in Future Drug Discovery.Molecules (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xianqin WeiInstitute of Entomology, College of Life Sciences, Nankai University, Tianjin 300071, China.
Weibin RuanInstitute of Entomology, College of Life Sciences, Nankai University, Tianjin 300071, China.
Klaas VrielingPlant Science and Natural Products, Institute of Biology, Leiden University, Sylviusweg 72, P.O. Box 9505, 2300 RA Leiden, The Netherlands.

Funding

National Key Research and Development Program of China 2019YFE0120400, 2018YFE0201002National Natural Science Foundation of China 31470495
6 · The paper itself

Abstract

Pyrrolizidine alkaloids (PAs) are a widespread group of secondary metabolites in plants. PAs are notorious for their acute hepatotoxicity, genotoxicity and neurological damage to humans and animals. In recent decades, the application of PAs for beneficial biological activities to cure disease has drawn greater attention. Here, we review the current knowledge regarding the pharmacological properties of PAs and discuss PAs as promising prototypes for the development of new drugs.

Indexed as

PlantsAnti-Infective AgentsAnti-Inflammatory AgentsAntineoplastic AgentsAntiviral AgentsPyrrolizidine AlkaloidsAnti-Infective AgentsAnti-Inflammatory AgentsAntineoplastic AgentsAntiviral AgentsPyrrolizidine Alkaloidsalkaloidsdefenseherb medicinepharmacyplant secondary metabolitesregulations

Identifiers

PMID33807368
PMCPMC8037423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.